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Abstract
Background: There are no overviews of systematic reviews investigating haemoglobin thresholds for transfusion.
This is important as the literature on transfusion thresholds has grown considerably in recent years. Our aim was to
synthesise evidence from systematic reviews and meta-analyses of the effects of restrictive and liberal transfusion
strategies on mortality.
Methods: This was a systematic review of systematic reviews (overview). We searched MEDLINE, Embase, Web of
Science Core Collection, PubMed, Google Scholar, and the Joanna Briggs Institute EBP Database, from 2008 to 2018.
We included systematic reviews and meta-analyses of randomised controlled trials comparing mortality in patients
assigned to red cell transfusion strategies based on haemoglobin thresholds. Two independent reviewers extracted
data and assessed methodological quality. We assessed the methodological quality of included reviews using
AMSTAR 2 and the quality of evidence pooled using an algorithm to assign GRADE levels.
Results: We included 19 systematic reviews reporting 33 meta-analyses of mortality outcomes from 53 unique
randomised controlled trials. Of the 33 meta-analyses, one was graded as high quality, 15 were moderate, and 17
were low. Of the meta-analyses presenting high- to moderate-quality evidence, 12 (75.0%) reported no statistically
significant difference in mortality between restrictive and liberal transfusion groups and four (25.0%) reported
significantly lower mortality for patients assigned to a restrictive transfusion strategy. We found few systematic
reviews addressed clinical differences between included studies: variation was observed in haemoglobin threshold
concentrations, the absolute between group difference in haemoglobin threshold concentration, time to
randomisation (resulting in transfusions administered prior to randomisation), and transfusion dosing regimens.
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Conclusions: Meta-analyses graded as high to moderate quality indicate that in most patient populations no
difference in mortality exists between patients assigned to a restrictive or liberal transfusion strategy.
Trial registration: PROSPERO CRD42019120503
Keywords: Anaemia, Red cell transfusion, Systematic review, Overview
Background
In 1999, the Transfusion Requirements in Critical Care
trial [1] was published. This trial randomised critical
care patients to either a restrictive or liberal red blood
cell transfusion strategy. Patients assigned to the restrict-
ive strategy were transfused if their haemoglobin con-
centration dropped below 70 g/L and concentrations
were maintained at 70 to 90 g/L. Patients assigned to the
liberal strategy were transfused if their haemoglobin
concentration dropped below 100 g/L with concentra-
tions maintained at 100 to 120 g/L. The authors con-
cluded “a restrictive strategy of red cell transfusion was
at least as effective and possibly superior to a liberal
haemoglobin strategy”. Since that study, many rando-
mised controlled trials (RCTs) evaluating restrictive and
liberal red cell transfusion strategies in a variety of pa-
tient populations have been published. Subsequently,
systematic reviews and meta-analyses synthesising the
results of these trials were conducted.
Systematic reviews of RCTs are considered the highest
level of evidence [2] and impact practice, the develop-
ment of clinical guidelines, and policy making. An over-
view of systematic reviews collates and appraises the
quality of previously conducted systematic reviews and
meta-analyses. No overview is available for the impact of
restrictive and liberal transfusion strategies. We con-
ducted this overview to critically appraise and summar-
ise the systematic reviews and meta-analyses describing
red cell transfusion strategies published to date [3].
A potential misconception surrounding studies investi-
gating pre-transfusion haemoglobin thresholds is that
the intervention of interest is red cell transfusion. How-
ever, these studies are not designed to test the efficacy of
transfusion as they do not compare red cell transfusion
to placebo or another intervention. Rather, the interven-
tion studied is the haemoglobin threshold, in other
words whether and to what extent lowering the haemo-
globin threshold for transfusion can be tolerated safely.
Therefore, where studies demonstrate restrictive transfu-
sion strategies are safe, the benefits include reducing the
number of transfusions, reducing patient exposure to
the hazards of transfusion, preservation of a finite re-
source, and reducing the significant hospital costs asso-
ciated with transfusion [4].
Our objective was to compare and contrast evidence
from systematic reviews and meta-analyses of the effects
of restrictive and liberal haemoglobin threshold strat-
egies on mortality. Specifically, our aim was to answer
whether mortality differed between systematic reviews
and meta-analyses of RCTs comparing restrictive to lib-
eral haemoglobin thresholds for red blood cell
transfusion.
Methods
Overviews of systematic reviews are a relatively new area
of research and a number of methodological approaches
exist. Our protocol is consistent with expert recommen-
dations published in a series of articles describing the
development and evaluation of overview methods [5, 6].
The protocol was registered on PROSPERO
(CRD42019120503) prior to commencing our review,
underwent peer-review, and was published [7]. It in-
cludes the review question, literature search strategy, in-
clusion and exclusion criteria, and methods for assessing
the quality of included reviews and the quality of evi-
dence presented. Formal ethics approval was not re-
quired for this overview as we only analysed published
literature.
Data sources and searches
We searched MEDLINE, Embase, Web of Science Core
Collection, PubMed (for prepublication, in process and
non-MEDLINE records), and the Joanna Briggs Institute
EBP Database on the 30 January 2019. A medical librar-
ian (RM) developed our search strategy, and this process
underwent internal peer review. In addition, we searched
Google Scholar and contacted experts in transfusion lit-
erature to identify additional studies. Our literature
search was restricted to studies published between 2008
and 2018. Details of our search strategy can be found in
the Additional file 1.
Study selection
Types of reviews
We included systematic reviews and meta-analyses of
RCTs published in the English language between 2008
and 2018. We restricted our search to this period as we
wanted to assess the most recent literature, and meta-
analyses are frequently updated. We excluded abstracts,
systematic reviews without meta-analyses, and system-
atic reviews and meta-analyses of observational studies.
We also excluded earlier meta-analyses that had been
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subsequently updated within our time period. Reviews of
observational studies were excluded because RCTs pro-
vide a complete summary of the effect different haemo-
globin thresholds for red cell transfusion have on
outcomes.
Participants
We included meta-analyses pooling patients randomised
to red cell transfusion strategies, with the exception of
meta-analyses of trials exclusively in neonatal and pre-
term infant populations.
Interventions/comparisons
We included meta-analyses of trials randomising pa-
tients to restrictive and liberal haemoglobin strategies as
defined by the study authors.
Outcomes
The primary outcome of interest for this overview is
mortality. We included any mortality time points re-
ported within the included reviews, including reviews
pooling mixed mortality time points. We also report red
cell utilisation outcomes including the proportion of pa-
tients receiving a red cell transfusion and the mean
number of units transfused. We a priori determined not
to report morbidity outcomes. While important, the def-
inition, grade, and severity of morbidity events pooled by
systematic reviews and meta-analyses vary considerably,
and as a result, interpretation is more subjective [8–10].
Data extraction and quality assessment
We designed electronic forms to collect the key charac-
teristics of included reviews. Two authors (KT, SF) inde-
pendently screened titles and abstracts for inclusion.
Discrepancies in article selections were resolved by dis-
cussion. Systematic reviews and meta-analyses are fre-
quently updated as new trials are published. Where a
review was updated, the most recent publication was
included.
The data collection process was performed with two
authors (KT, SF) independently extracting data from sys-
tematic reviews and meta-analyses and entering these on
pre prepared data extraction forms. All disagreements in
data extraction were resolved by discussion. When re-
quired, study authors were contacted for additional data
or clarifications.
We used an electronic data extraction form to record
data on author details, year of publication, clinical set-
ting, inclusion criteria, exclusion criteria, number of par-
ticipants randomised, number of included studies, mean
units transfused, proportion of patients transfused, mor-
tality time points reported, subgroups reported, descrip-
tion of individual trial interventions (haemoglobin
thresholds) pooled, description of timing of interven-
tions, and description of risk of bias assessments.
We assessed the methodological quality of included re-
views in duplicate using the 16 domains described in the
Assessing the Methodological Quality of Systematic
Reviews (AMSTAR 2) tool [11]. This tool assesses im-
portant aspects of systematic reviews including address-
ing heterogeneity and investigating publication bias
(Additional file 1: Table S1). Differences were resolved
by discussion, and a full summary of results is presented
in graphical format. We included information on
whether individual systematic reviews and meta-analyses
included a risk of bias assessment of individual trials,
and what tools were used.
Two authors (KT and SF) independently evaluated the
quality of evidence pooled within the systematic reviews
and meta-analyses using a previously applied algorithm
specifically developed to assign GRADE levels of evi-
dence for overviews [12]. This algorithm uses the num-
ber of participants pooled, risk of bias, statistical
heterogeneity, and the methodological quality of system-
atic reviews [13], to assess imprecision, risk of bias (trial
quality and review quality), and inconsistency. Results
are categorised into four levels of quality: high, moder-
ate, low, or very low. More detailed information on how
the final GRADE level is determined is presented in
Additional file 1: Table S2.
We chose this approach to improve the transparency
and consistency of our assessments [6]. Disagreements
were minor in nature and resolved through discussion.
Based on the definitions of quality of evidence grades
presented in the GRADE Handbook (Additional file 1:
Table S3) [14], we interpreted high and moderate
GRADE levels to represent strong evidence. This ap-
proach has been previously described [15]. A low
GRADE means that confidence in the result is limited as
the true effect may be substantially different from the
estimate.
Data synthesis and analysis
We expected to find significant overlap of RCTs in-
cluded in the meta-analyses. As we did not exclude any
systematic reviews based on overlap, we decided a priori
not to combine the results from the included meta-
analyses and instead present the results descriptively in
the text, figures, and tables. The results of included
meta-analyses were presented as rate ratios with 95%
confidence intervals. As per our protocol, we planned to
convert any meta-analysis results presenting odds ratios
to rate ratios. However, our primary outcome was mor-
tality, and mortality events were low. Given the rate ra-
tio, risk ratio, and odds ratio are approximately the same
when comparing groups with low event rates, we made a
decision not to convert odds ratios to risk ratios. Instead,
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we included the results of these relative risks as pre-
sented by the meta-analyses making a note of what
measure was used.
Our analysis presents results comparing restrictive to
liberal thresholds; therefore, the ratios and 95% confi-
dence intervals of any meta-analyses comparing liberal
to restrictive are inversed.
Patient and public involvement
It was not possible or appropriate to involve patients or
the public in this work as it involved a summary of re-
search already conducted.
Results
Figure 1 summarises the number of studies identified,
screened, and included in our study. Our database
search identified 336 records, and a further 10 were
identified from Google Scholar, with no additional stud-
ies identified after contacting experts in transfusion lit-
erature. After duplicates were removed, our literature
search returned 234 records, of which 191 were ex-
cluded on abstract review. Forty-three full-text articles
were retrieved and assessed for eligibility.
Of these, we excluded 24 studies [9, 16–38] for the fol-
lowing reasons: seven were abstracts [16, 21, 22, 24, 25,
27, 31], five presented mortality from one trial [28, 29,
32, 33, 38], three did not include a meta-analysis [19, 26,
34], three pooled non-randomised trials [20, 35, 37], and
six were updated by more recent reviews (Additional file
1: Table S4) [9, 17, 18, 23, 30, 36]. Nineteen systematic
reviews provided 33 meta-analyses that satisfied the eli-
gibility criteria of our overview [8, 39–56].
Table 1 presents the characteristics of the included
systematic reviews and meta-analyses. The number of
individual trials pooled in each systematic review
ranged from 3 [54] to 37 [40], with the total number
of patients randomised ranging from 733 [47] to 19,
049 [40]. The majority of systematic reviews pooled
results from mixed medical and surgical settings (six
reviews) [8, 40, 42, 43, 54, 56]. Following this, the
most common clinical settings pooled were ortho-
paedic surgery (five reviews) [39, 44, 48–50], surgical
and critical care (three reviews) [41, 45, 52], cardiac
surgery (two reviews) [46, 55], acute upper gastro-
intestinal bleeding (one review) [51], critical care and
acute coronary syndrome (one review) [53], and
haematology/oncology (one review) [53].
Fig. 1 PRISMA flow diagram
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Table 1 Characteristics of included reviews
First author Year Population Total
no. of
patients
Total
no.
of
trials
Proportion
transfused
RBCs
Mean
difference
in units
transfused
Describes
timing of
intervention
Mortality
time points
pooled in
meta-
analyses
Subgroups presented for
mortality outcome
Brunskill 2015 Patients undergoing
surgery for hip fracture
2722 6 R: 38%,
L: 96%*
NR Y 30-day; 60-
day; 90-day
Carson 2018 Adults or children
admitted for surgical or
medical care
19,049 37 R: 50%,
L: 81%
NR N 30-day Total; cardiac surgery; acute
myocardial infarction
Chong 2018 Adult surgical or
critically ill patients
10,797 27 NR Critical
care 1.7,
surgical
1.3
N 30-day; late
mortality (60
to 365 days);
in-study
Critical care; surgical
Cortes-Puch 2018 Patients with and
without cardiovascular
disease
14,397 17 NR NR N 30-day or
in-hospital
Cardiovascular disease
patients hospitalised for non-
cardiac reasons; for percutan-
eous coronary interventions;
for cardiac surgery
Docherty 2016 Adults with
cardiovascular disease
not undergoing cardiac
surgery
3033 11 R: 41%,
L: 96%*
NR N 30-day Total; Stratified by
cardiovascular disease
Gu 2018 Adult patients
undergoing orthopaedic
surgery
3968 10 NR NR N 30-day
Holst 2015 Adults or children
admitted for surgical or
medical care
9813 31 R: 45%,
L: 86%
1.43 N Mixed
(unspecified)
Low risk of bias trials
Hovaguimian 2016 Adult surgical or
critically ill patients
12,052 31 NR NR N Within 30
days
Cardiovascular disease
undergoing cardiac or
vascular procedures; patients
with cardiovascular disease
undergoing orthopaedic
surgery; surgical and medical
patients admitted to an acute
care facility
Kheiri 2018 Patients undergoing
cardiac surgery
9005 9 R: 52%,
L: 76%
NR Y Within 30
days
Luo 2018 Haematology/oncology 733 5 NR 0.33 N 60-day
Mao 2017 Adults undergoing hip
or knee surgery
3788 10 R: 36%,
L: 74%
NR N 30-day
Melchor 2016 Critically ill adults
admitted to intensive
care units and/or with
acute coronary
syndrome
2159 6 R: 63%,
L: 99%
NR Y Mixed
(longest
term)
Critical care; coronary artery
disease
Mitchell 2017 Adults undergoing hip
or knee surgery or hip
fracture repair
3783 9 R: 39%,
L: 81%
0.95 N Mixed
(unspecified)
Muller 2018 Patients undergoing
major orthopaedic
surgery
3693 8 R: 36%,
L: 82%
NR N 30-day
Odutayo 2017 Patients 16 years and
older with acute upper
gastrointestinal bleeding
1965 5 NR 1.73 N Mixed
Patel 2015 Adult patients
undergoing cardiac
surgery, adult and
paediatric critically ill or
noncardiac surgical
11,713 25 NR NR N 30-day Cardiac surgery; non-cardiac
surgery
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Of the 19 included systematic reviews and meta-
analyses, 16 did not restrict their literature searches by
language [8, 39, 40, 42–47, 50–56]. One review restricted
their search to publications in the English language [49],
while the language restrictions of the search strategies of
two reviews were unclear [41, 48]. Eight reviews did not
restrict their search strategy by publication status [8, 39,
40, 43, 44, 48, 54, 55], two reviews restricted their search
results to trials published as full reports [45, 53], while
the publication status restriction of the other nine re-
views were unclear [41, 42, 46, 47, 49–52, 56].
Figure 2 presents a matrix of unique RCTs pooled by
the 19 systematic reviews and meta-analyses. Signifi-
cant overlap between the included systematic reviews
and meta-analyses exists. Sixty-eight unique RCTs
were pooled by the included systematic reviews and
meta-analyses. Of these 68, 53 unique RCTs were in-
cluded in the pooled analyses for mortality. Unique
RCTs were included in a median of two meta-
analyses (range one to 13).
Comparison of patients transfused
Eight of the 19 reviews reported the pooled proportion
of patients transfused between restrictive and liberal
groups [8, 40, 46, 48–50, 53, 55], with a further three re-
views providing enough information for the difference to
be calculated [39, 43, 56]. In the restrictive arm, the pro-
portion of patients transfused ranged from 36% [48, 50]
to 63% [53], while in the liberal arm the proportion
ranged from 74% [48] to 99% [53].
Units of blood transfused
Seven of the 19 reviews reported the pooled mean differ-
ence in units of red cells transfused between restrictive
and liberal transfusion arms [8, 41, 47, 49, 51, 54, 55],
with the mean difference ranging from 0.33 [47] to 1.98
[54] mean units. The smallest difference in mean units
transfused was from the meta-analysis by Luo et al. [47].
The largest difference in mean units was from the sys-
tematic review by Salpeter et al. [54]. Among the indi-
vidual RCTs pooled, the smallest mean difference in
units of red cells transfused between groups was 0.08,
comparing a mean of 0.78 units transfused in the re-
strictive arm to a mean of 0.86 units transfused in the
liberal [57]. These differences are largely explained by
the definition of restrictive and liberal haemoglobin
thresholds used in the included studies.
Haemoglobin concentration
Almost all reviews reported the pooled difference in
planned intervention haemoglobin thresholds for re-
strictive and liberal groups. This difference ranged
from 0 to 30 g/L among restrictive groups, with one
study [54] only pooling trials with restrictive thresh-
olds below 70 g/L and three studies [8, 45, 47] pool-
ing trials with restrictive thresholds ranging from 70
to 100 g/L. The difference in thresholds in the liberal
groups ranged from 10 to 53 g/L, with four studies
pooling trials with liberal thresholds ranging from 90
to 100 g/L [51–54] and one study pooling trials ran-
ging from 80 to 133 g/L (Fig. 3) [45].
Only one review described the actual difference in
mean haemoglobin thresholds between groups [39]. This
review reported the result from one trial with a planned
difference in haemoglobin thresholds of 20 g/L, with a
threshold of below 80 g/L for the restrictive group and
below 100 g/L for liberal. The actual mean difference in
haemoglobin level before transfusion in this trial was
smaller, with a 13 g/L higher mean difference in the lib-
eral group.
Table 1 Characteristics of included reviews (Continued)
First author Year Population Total
no. of
patients
Total
no.
of
trials
Proportion
transfused
RBCs
Mean
difference
in units
transfused
Describes
timing of
intervention
Mortality
time points
pooled in
meta-
analyses
Subgroups presented for
mortality outcome
patients
Salpeter 2014 Adults or children
admitted for surgical or
medical care
2364 3 NR 1.98 N In-hospital,
30-day, total
Shehata 2018 Adults or paediatric
patients undergoing
cardiac surgery
9092 13 R: 53%,
L: 78%
0.90 Y Within 30
days
Adult patients; paediatric
patients
Simon 2017 Adults admitted for
surgical or medical care
where a substantial
proportion of the trial
population was older
than 65 years
5780 9 R: 52%,
L: 77%*
NR N 30-day; 90-
day
R restrictive strategy, L liberal strategy, RBC red blood cell, NR not reported
*Calculated from data presented in tables and figures
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Fig. 2 Matrix of randomised controlled trials pooled by the 19 included systematic reviews and meta-analyses
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Transfusion dosing regimens
There was a lack of clarity around transfusion dosing
regimens pooled between trials. Three reviews described
the different planned post-transfusion haemoglobin tar-
gets or planned units of blood to be transfused, accord-
ing to the trial protocols [39, 40, 53]. The criteria for
and amount transfused differed between trials and
within trials.
Timing of randomisation
The timing of randomisation varied between individ-
ual trials, with some interventions commencing on
admission, some intraoperatively, some after surgery,
and others during a portion of a patient’s hospital
stay; however, this information was reported only in
four reviews [39, 46, 53, 55].
Assessment of methodological quality and quality of
evidence
Detailed information on the methodological quality of
included systematic reviews and meta-analyses is
provided in Fig. 4. Using the 16 domains of the
AMSTAR 2 tool, two reviews were of a high quality [8,
53], one was moderate [39], 10 were low [42, 43, 45, 47,
49, 51, 52, 54–56], and six were critically low [40, 41, 44,
46, 48, 50]. Figure 5 presents the assessment of the qual-
ity of evidence using the GRADE tool. The 19 included
systematic reviews presented 33 meta-analyses on mor-
tality. Of the 33 meta-analyses, one was high quality, 15
were moderate, 17 were low, and none were very low.
More detailed information is available in Additional file
1: Table S5. The reasons for downgrading the quality of
evidence to moderate or low included poor methodo-
logical quality as measured by AMSTAR 2, heterogeneity
between study results, the inclusion of trials with a high
risk of bias, and low numbers of participants pooled.
Mortality
The most common mortality time point pooled was
30 days with 11 reviews presenting a meta-analysis of
30-day mortality [39–41, 43, 44, 46, 48, 50, 52, 54,
56] and a further three reviews pooling mortality
Fig. 3 Range in restrictive and liberal haemoglobin thresholds pooled by systematic reviews and meta-analyses. Size of the markers represents
number of trials
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within 30 days [42, 45, 55]. Four reviews presented a
meta-analysis of mixed mortality time points [8, 51,
53, 54], two reviews presented the results of 60-day
mortality [39, 47], two reviews of 90-day mortality
[39, 56], one review captured in-hospital mortality
[54], and one review did not describe the mortality
time points pooled [49].
We contacted one study author to clarify the mor-
tality time point pooled in their meta-analysis of car-
diac surgery. The main outcome for this systematic
review was 30-day mortality; however, the study ap-
plied the 90-day mortality from one large trial [52].
As this trial was likely to significantly influence the
pooled estimate, we present a re-calculated odds ra-
tio for 30-day mortality (Additional file 1: Table S6).
Figure 5 presents the relative risks for mortality in
patients assigned to restrictive transfusion thresholds
when compared with liberal thresholds. Of the 33
meta-analyses, 25 (75.8%) reported no statistically sig-
nificant difference between restrictive and liberal
transfusion thresholds, with significance set at the 5%
level. Five (15.1%) reported restrictive transfusion
thresholds resulted in significantly fewer deaths, while
3 (9.1%) reported liberal transfusion strategies resulted
in fewer deaths.
High to moderate GRADE ratings
Of the 33 meta-analyses identified, 16 were graded as high-
to moderate-quality of evidence. Of these, 12 (75.0%)
reported no statistically significant difference in mortality
between restrictive and liberal transfusion groups and four
(25.0%) reported significantly lower mortality for patients
assigned to a restrictive transfusion strategy.
Only the meta-analysis by Holst et al. [8] was graded as
high-quality evidence for mortality. This review reported a
risk ratio for mortality of 0.86 with a restrictive transfusion
strategy (95% CI 0.74 to 1.01, p = 0.07) when compared
with a liberal strategy. The four meta-analyses graded as
moderate quality of evidence, reporting significantly fewer
deaths in patients assigned to a restrictive transfusion
strategy were from two systematic reviews [51, 54]. One of
these reviews [51] only included patients with gastrointes-
tinal bleeding. The other meta-analyses were in the review
by Salpeter et al. [54]. This systematic review differed from
all the other reviews as it included trials where the re-
strictive strategy only allowed red cell transfusion at
haemoglobin concentration of less than 70 g/L.
Discussion
Our overview identified 19 systematic reviews report-
ing 33 meta-analyses comparing mortality in patients
Fig. 4 Assessing methodological quality of systematic reviews
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assigned to restrictive and liberal transfusion strat-
egies. Among meta-analyses with high- to moderate-
quality evidence for mortality, 75% reported no statis-
tically significant difference between patients assigned
to restrictive and liberal transfusion strategies, while
25% reported lower mortality with restrictive transfu-
sion strategies. The meta-analyses reporting signifi-
cantly fewer deaths in patients assigned to restrictive
transfusion strategies differed in that one only in-
cluded patients with gastrointestinal bleeding, while
the others only evaluated patients assigned to a more
restrictive haemoglobin threshold (below 70 g/L).
The identified meta-analyses with high- to moderate-
quality evidence for mortality studied the following
clinical settings: cardiac surgery, non-cardiac surgery,
cardiovascular disease with and without cardiac surgery,
critical care, gastrointestinal bleeding, and mixed clinical
settings. Meta-analyses pooling mixed clinical settings
included similar patient groups in addition to septic
shock, trauma, and acute myocardial infarction. Al-
though there may be limits to generalisability in some
specific patient populations, the results from these stud-
ies indicate that a restrictive compared to a liberal trans-
fusion strategy in most patient populations reduces the
number of patients exposed to red cell transfusion and
the number of red cell units transfused, and show that
no difference in mortality exists.
These findings support the conclusions of evidence-
based guidelines and reassure clinicians that restrictive
transfusion thresholds can be applied in most patient
populations. For example, guidelines from Australia,
based on systematic reviews of available evidence,
conclude that transfusion is usually inappropriate at
haemoglobin concentrations above 90 g/L, and between
70 and 90 g/L transfusion is not associated with reduced
mortality. Below 70 g/L transfusion may be appropriate;
however, it may not be required in well-compensated
patients where other specific therapy is available [58–62].
A number of other clinical practice guidelines and reviews
recommend restrictive thresholds of 70 to 80 g/L for most
clinical settings [63–65]. The results of future high-quality
research may address uncertainty in specific clinical set-
tings such as patients with acute coronary syndrome and
haematology/oncology patients.
Limitations of systematic reviews and meta-analyses
The quality of RCTs pooled by systematic reviews and
meta-analyses are generally appraised through tools de-
signed to assess the risk of bias and the quality of evi-
dence. These tools focus on important elements in the
Fig. 5 Relative risks (95% CI) for mortality from meta-analyses comparing restrictive and liberal red cell transfusion thresholds. ND = not defined;
†, odds ratios presented; *, odds ratio recalculated to reflect 30-day mortality
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conduct of RCTs such as concealed allocation, blinding,
random allocation, selective reporting, statistical incon-
sistency (or heterogeneity), imprecision, indirectness,
and publication bias.
While these domains are important in the general con-
text of reviewing RCTs, we identified key clinical differ-
ences in the RCTs comparing transfusion strategies.
Some, including variability in the study setting, variabil-
ity in the patient population, and variability in the timing
of the outcome measure, apply to all systematic reviews.
Four, however, are unique to this topic: (1) haemoglobin
thresholds selected for transfusion, (2) the absolute dif-
ference of pre-transfusion haemoglobin concentrations,
(3) time to randomisation (resulting in transfusion ad-
ministered prior to randomisation), and (4) comparable
transfusion dosing regimens.
We identified examples of systematic reviews attempt-
ing to address aspects of these issues. For example, the
systematic review by Salpeter et al. [54] addressed differ-
ences in restrictive haemoglobin thresholds pooled by
including trials with the same threshold for restrictive
transfusions. This may explain why their finding of sig-
nificantly lower mortality differed to the majority of
other meta-analyses. However, the majority of systematic
reviews pooled trials with a variety of restrictive and lib-
eral transfusion strategies that included haemoglobin
concentrations ranging from 70 to 100 g/L and 80 to
133 g/L. This means the haemoglobin concentrations
used in some restrictive strategies were higher than
those in some liberal strategies.
None of the systematic reviews and meta-analyses in-
cluded in this overview accounted for the variation in
absolute difference in haemoglobin threshold concentra-
tions between restrictive and liberal protocols within tri-
als. This varied considerably with systematic reviews
pooling trials with a difference from 10 g/L (including
trials comparing restrictive thresholds of 70, 80, or 90 g/
L with liberal thresholds of 80, 90, or 100 g/L respect-
ively) to 40 g/L (including a trial comparing a restrictive
threshold of 80 g/L with 120 g/L). Further confounding
this issue is the change in difference between haemoglo-
bin thresholds defined in transfusion protocols and the
actual resulting difference in haemoglobin concentration
prior to transfusion observed throughout the trial. For
example, one systematic review [39] reported that one
trial compared a difference in haemoglobin concentra-
tion thresholds between transfusion protocols of 20 g/L
(80 g/L compared with 100 g/L); however, the actual
mean difference in haemoglobin level before transfusion
was 13 g/L.
One systematic review [55] addressed the important
issue of timing of randomisation in their review of car-
diac surgery RCTs by conducting a sub-group analysis of
trials randomised intraoperatively and trials randomised
postoperatively. In some trials, many participants have
had a red cell transfusion prior to randomisation that is
not included in the analysis. This potentially introduces
bias into the estimate of risk for the specified outcome.
The least discussed of the identified issues was the lack
of comparable transfusion dosing regimens between
studies. Some RCTs set protocols for post transfusion
haemoglobin targets to determine the amount of blood
to transfuse, others indicated the number of units to
transfuse when the haemoglobin threshold was met, and
others were unclear. Of the 19 systematic reviews we in-
cluded, only three referred to these differences. These
differences may explain the large variation in the actual
number of units transfused between restrictive and lib-
eral groups between studies pooled, which was as low as
a mean difference of less than half a unit in one system-
atic review to a high of two units in another.
These issues are relevant because they may result in
smaller than expected differences in transfusion rates
and transfused units between groups, and skew the re-
sults towards no statistically significant differences in
outcome. We recommend that systematic reviews and
meta-analyses comparing outcomes in restrictive and
liberal transfusion trials be interpreted with these issues
in mind.
Limitations of our overview
A potential limitation of our overview of systematic re-
views was that we restricted our literature search to re-
views published in the English language. It is unlikely
this has had any substantive influence on our findings as
16 of the 19 included systematic reviews had an unre-
stricted search by language.
We limited our search to systematic reviews and
meta-analyses published between 2008 and 2018. We
made this decision because systematic reviews and
meta-analyses are frequently updated as new trials are
published. However, this restriction did not mean trials
published prior to 2008 were excluded, as the systematic
reviews and meta-analyses included in our overview
pooled trials without date restrictions.
We restricted the primary outcome of our overview to
mortality, and as a result, any morbidity outcomes re-
ported were not included. Though these outcomes are
important, and frequently reported in trials as secondary
outcomes, they have limitations. Authors of systematic
reviews have highlighted this limitation and recom-
mended caution in interpretation due to their subjective
nature [8–10].
Conclusions
This overview of reviews evaluating the effect on mortal-
ity of restrictive and liberal transfusion strategies identi-
fied 19 systematic reviews and 33 meta-analyses that
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used data from 53 RCTs. Of the 33 meta-analyses, one
was graded as high quality, 15 were moderate, and 17
were low. The 16 meta-analyses of mortality graded as
high to moderate quality demonstrate no difference in
mortality between these two transfusion strategies.
Australian guidelines state that red cell transfusion
should not be dictated solely by haemoglobin concentra-
tion; rather, the decision should also be based on a pa-
tient’s clinical signs and symptoms, the availability of
other therapies for the treatment of anaemia, and the
presence of risk factors for haemorrhage [58–62]. Simi-
larly, the AABB Clinical Practice Guidelines highlight it
is a good practice to individualise transfusion decisions
taking into account the overall clinical context, haemo-
globin decline, symptoms, volume status, patient prefer-
ences, and alternative therapies [63]. Therefore,
important questions for future research include examin-
ing whether haemoglobin concentration is a good indi-
cator of tissue oxygen needs and looking at other
physiological parameters to assess whether these would
be more indicative of tissue oxygenation and perfusion.
Should future systematic reviews and meta-analyses
comparing transfusion thresholds be updated, we recom-
mend they address the variations between studies in
haemoglobin thresholds selected for transfusion, the gap
in haemoglobin thresholds between restrictive and lib-
eral groups both planned and actual, the different timing
of randomisation, and the lack of comparable transfu-
sion dosing regimens.
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